Mitchell Sinkler & Starr PA trimmed its position in Bristol-Myers Squibb Co (NYSE:BMY) by 19.0% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 8,550 shares of the biopharmaceutical company’s stock after selling 2,000 shares during the period. Mitchell Sinkler & Starr PA’s holdings in Bristol-Myers Squibb were worth $408,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the stock. Vanguard Group Inc increased its position in Bristol-Myers Squibb by 1.0% during the third quarter. Vanguard Group Inc now owns 128,376,159 shares of the biopharmaceutical company’s stock worth $7,969,593,000 after buying an additional 1,229,553 shares during the last quarter. BlackRock Inc. increased its position in Bristol-Myers Squibb by 0.9% during the fourth quarter. BlackRock Inc. now owns 115,573,078 shares of the biopharmaceutical company’s stock worth $6,007,489,000 after buying an additional 999,193 shares during the last quarter. Dodge & Cox increased its position in Bristol-Myers Squibb by 0.8% during the third quarter. Dodge & Cox now owns 32,969,186 shares of the biopharmaceutical company’s stock worth $2,046,727,000 after buying an additional 264,100 shares during the last quarter. Northern Trust Corp increased its position in Bristol-Myers Squibb by 4.4% during the fourth quarter. Northern Trust Corp now owns 22,576,884 shares of the biopharmaceutical company’s stock worth $1,173,547,000 after buying an additional 954,877 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its position in Bristol-Myers Squibb by 1.1% during the fourth quarter. Bank of New York Mellon Corp now owns 17,303,884 shares of the biopharmaceutical company’s stock worth $899,456,000 after buying an additional 180,711 shares during the last quarter. 74.28% of the stock is currently owned by institutional investors and hedge funds.

A number of equities analysts have weighed in on the company. Zacks Investment Research downgraded Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a research report on Thursday, March 28th. BMO Capital Markets boosted their price target on Bristol-Myers Squibb from $62.00 to $63.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 17th. ValuEngine downgraded Bristol-Myers Squibb from a “sell” rating to a “strong sell” rating in a research report on Thursday, April 4th. Bank of America lowered their price target on Bristol-Myers Squibb from $53.00 to $51.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 19th. Finally, Edward Jones downgraded Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Friday, January 4th. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and six have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $59.14.

Shares of NYSE:BMY opened at $45.52 on Monday. Bristol-Myers Squibb Co has a 12-month low of $44.30 and a 12-month high of $63.69. The company has a market cap of $74.38 billion, a PE ratio of 11.44, a PEG ratio of 2.34 and a beta of 0.79. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.61 and a quick ratio of 1.50.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, January 24th. The biopharmaceutical company reported $0.94 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.85 by $0.09. Bristol-Myers Squibb had a return on equity of 48.99% and a net margin of 21.95%. The company had revenue of $5.97 billion during the quarter, compared to analysts’ expectations of $5.95 billion. During the same quarter in the previous year, the company posted $0.68 earnings per share. The business’s revenue was up 9.6% on a year-over-year basis. As a group, sell-side analysts predict that Bristol-Myers Squibb Co will post 4.16 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 1st. Stockholders of record on Friday, April 5th will be issued a dividend of $0.41 per share. This represents a $1.64 dividend on an annualized basis and a dividend yield of 3.60%. The ex-dividend date is Thursday, April 4th. Bristol-Myers Squibb’s dividend payout ratio is presently 41.21%.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The legal version of this piece of content can be read at https://www.watchlistnews.com/mitchell-sinkler-starr-pa-cuts-stake-in-bristol-myers-squibb-co-bmy/2980817.html.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

Further Reading: Hedge Funds – Risk or Reward?

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.